GRACE

cancergrace.org

 

Lung
04:01

GRACE

Lung Resection in Early Stage NSCLC: An Overview

FEATURING Chi-Fun Jeffrey Yang
  • 172 views
  • May 15, 2024
  • 1
05:58

GRACE

Future Goals of mNSCLC Treatment

FEATURING Puneeth Iyengar
  • 53 views
  • May 15, 2024
06:13

GRACE

The NRG-LU Trial: Maintenance Systemic Therapy vs. Local Consolidative Therapy + Systemic Therapy in Patients With Limited mNSCLC

FEATURING Puneeth Iyengar
  • 44 views
  • May 15, 2024
06:14

GRACE

Using Radiation to Improve Outcomes and QoL in Patients With mNSCLC

FEATURING Puneeth Iyengar
  • 2 views
  • May 15, 2024
02:41

GRACE

Staging Disease: How Oncologists Stage NSCLC

FEATURING Ibiayi Dagogo-Jack, Millie Das, Chi-Fun Jeffrey Yang
  • 489 views
  • May 1, 2024
03:19

GRACE

Biomarkers in NSCLC

FEATURING Ibiayi Dagogo-Jack, Millie Das, Chi-Fun Jeffrey Yang
  • 157 views
  • May 1, 2024
  • 1
06:09

GRACE

Perioperative vs. Preoperative Surgery in NSCLC

FEATURING Ibiayi Dagogo-Jack, Millie Das, Chi-Fun Jeffrey Yang
  • 287 views
  • May 1, 2024
03:25

GRACE

Antibody Drug Conjugates and How They Are Used in NSCLC

FEATURING Lyudmila Bazhenova
  • 10 views
  • May 1, 2024
02:36

GRACE

ADC Treatment in NSCLC

FEATURING Lyudmila Bazhenova
  • 9 views
  • May 1, 2024
03:15

GRACE

Bispecific Antibodies in Lung Cancer

FEATURING Lyudmila Bazhenova
  • 7 views
  • May 1, 2024
02:52

GRACE

Amivantamab in 1L Advanced NSCLC With EGFR exon 20 Insertion Mutations

FEATURING Lyudmila Bazhenova
  • 18 views
  • May 1, 2024
05:47

GRACE

Treatment Options for EGFR+ NSCLC

FEATURING Ibiayi Dagogo-Jack, Natalie Vokes
  • 19 views
  • June 26, 2023
03:42

GRACE

Surgical Options for Stage IV NSCLC With Brain Metastases: 60 y/o Woman With Headache, Nausea, and Gait Imbalance

FEATURING Ibiayi Dagogo-Jack, Joshua Reuss
  • 5 views
  • June 26, 2023
06:02

GRACE

Neoadjuvant Chemo +/- Nivo for Patients With Early Stage NSCLC: Case-Based Panel Discussion

FEATURING Ibiayi Dagogo-Jack, Joshua Reuss
  • 82 views
  • May 9, 2023
03:21

GRACE

Treating Stage III NSCLC: Case-Based Panel Discussion

FEATURING Ibiayi Dagogo-Jack, Kathryn Arbour
  • 12 views
  • May 9, 2023
03:44

GRACE

How Oncologists Stage Disease - Case-Based Panel Discussion: 50 y/o Female With Stage IIIA NSCLC

FEATURING Ibiayi Dagogo-Jack, Joshua Reuss, Natalie Vokes, Kathryn Arbour
  • 12 views
  • May 9, 2023
09:37

GRACE

Is Broad NGS the Standard of Care in Advanced NSCLC?

FEATURING Ibiayi Dagogo-Jack, Melina Marmarelis, Adrian Sacher, Aparna Hegde
  • 126 views
  • June 3, 2022
05:27

GRACE

Neoadjuvant Therapy vs. Adjuvant Therapy in NSCLC: What Is the Future Role?

FEATURING Jack West, Estelamari Rodriguez, Riyaz Shah, Narjust Duma
  • 93 views
  • June 3, 2022
  • 1
05:38

GRACE

Surgical vs. Nonsurgical Treatment in Early NSCLC

FEATURING Jack West, Estelamari Rodriguez, Riyaz Shah, Narjust Duma
  • 81 views
  • June 3, 2022
  • 1
07:28

CancerGRACE

Early Stage NSCLC: PD-L1 and Durvalumab

FEATURING Jack West, Estelamari Rodriguez, Riyaz Shah, Narjust Duma
  • 77 views
  • June 3, 2022
  • 1
04:35

GRACE

Testing in Potentially Resectable & Unresectable Locally Advanced NSCLC

FEATURING Jack West, Estelamari Rodriguez, Riyaz Shah, Narjust Duma
  • 90 views
  • June 3, 2022
  • 1
22:49

CancerGRACE

The Need for Broad Molecular Testing for Driver Mutations in NSCLC

FEATURING Justin Gainor
  • 100 views
  • May 23, 2021
26:08

GRACE

NSCLC Frontline Therapy for Uncommon Mutations: Overview of RET, NTRK, MET & BRAF & Available Agents

FEATURING Justin Gainor
  • 100 views
  • May 20, 2021
06:15

CancerGRACE

Expert Discussion on Targeted Therapy for mNSCLC: Can ALK Inhibitors Treat and Prevent Brain Mets?

FEATURING Jack West
  • 31 views
  • March 31, 2021
18:10

GRACE

A Case of a NSCLC KRAS 71 y/o Female With Underlying Autoimmune Condition: What Treatment Options Exist & What Comes Next?

FEATURING Stephen Liu, Julie Brahmer, Benjamin Levy
  • 69 views
  • March 31, 2021
15:42

CancerGRACE

Expert Analysis of 1L EGFR+ Advanced NSCLC Options: 1st Gen Gefitinib & Erlotinib, 2nd Gen Afatinib & Dacomitinib, 3rd Gen Osimertinib, Combos With VEGF or Chemo, Exon 20 Insertions

FEATURING Jared Weiss
  • 197 views
  • March 1, 2021
  • 1
10:33

GRACE

Targeted Therapy for EGFR+ NSCLC: How Do We Think About Acquired Resistance? How to Assess for Osimertinib Resistance?

FEATURING Zofia Piotrowska
  • 103 views
  • March 1, 2021
  • 1
18:15

CancerGRACE

Targeted Therapy for EGFR+ NSCLC: What Are the Current Options Upon Acquired Resistance to Osimertinib?

FEATURING Zofia Piotrowska
  • 98 views
  • March 1, 2021
  • 1
05:41

GRACE

ASCO Expert Discussion on Malignant Pleural Mesothelioma: Does Durvalumab Added to Standard Chemo Improve OS?

FEATURING Jack West, Helena Yu, David Spigel
  • 24 views
  • January 30, 2021
05:47

GRACE

ASCO Roundtable on 2L Malignant Pleural Mesothelioma: How Encouraging Is Ramucirumab/Gemcitabine Combination?

FEATURING Jack West, Helena Yu, David Spigel
  • 97 views
  • January 30, 2021
10:25

CancerGRACE

IO for Unresectable Stage 3 NSCLC: Does Durvalumab Help Patients? What Are the Leading Treatment Options for Patients With Low / Negative PD-L1 Expression?

FEATURING Millie Das
  • 58 views
  • January 21, 2021
08:13

CancerGRACE

2020 ASCO Highlights on RT+ Chemo in LS-SCLC: Is There a Difference in Efficacy & Toxicity Between Lower vs. Higher Dose Twice Daily?

FEATURING Jack West, Helena Yu, David Spigel
  • 55 views
  • December 10, 2020
16:22

GRACE

2020 ASCO ADAURA Trial Update on Adjuvant Osimertinib in EGFR+ NSCLC: What Is the Clinical Impact? Should We Be Concerned About the Lack of OS Data?

FEATURING Helena Yu, David Spigel, Jack West
  • 186 views
  • December 1, 2020
11:28

CancerGRACE

2020 ASCO Update on 1L Advanced NSCLC: Is Nivo + Ipi + Limited Course of Chemo More Beneficial for OS vs. 4 Cycles of Chemo?

FEATURING Helena Yu, David Spigel, Jack West
  • 104 views
  • November 30, 2020
11:22

CancerGRACE

2020 ASCO Update on Advanced NSCLC: What Is the Role for Nivolumab/Ipilimumab Combination Today?

FEATURING Helena Yu, David Spigel, Jack West
  • 120 views
  • November 30, 2020
09:02

CancerGRACE

2020 ASCO Update on MET/RET+ NSCLC: How Promising Are Capmatinib & Pralsetinib?

FEATURING Helena Yu, David Spigel, Jack West
  • 112 views
  • November 30, 2020
  • 1
08:25

CancerGRACE

2020 ASCO Update on HER2+ NSCLC: Is There a Promising Clinical Activity With T-DXd?

FEATURING Helena Yu, David Spigel, Jack West
  • 12 views
  • November 30, 2020
12:16

CancerGRACE

2020 ASCO Update on EGFR+ NSCLC: Does Upfront SBRT to Sites at Diagnosis Along With 1L TKI Improve PFS/OS vs. TKI Alone?

FEATURING Helena Yu, David Spigel, Jack West
  • 563 views
  • November 30, 2020
  • 1
08:16

CancerGRACE

ASCO 2020 Updates on PD-L1 NSCLC: Is Tiragolumab+Atezo Beneficial for ORR/PFS vs. Atezo+Placebo?

FEATURING Jack West, Helena Yu, David Spigel
  • 69 views
  • November 27, 2020
05:32

GRACE

2020 Updates on SCLC: Have We Progressed in the Treatment of Relapsed Disease? Is FDA-Approved Lurbinectedin a New SoC? Are Pembro & Nivo Beneficial Options for ES & PDL1 Patients?

FEATURING Taofeek Owonikoko
  • 219 views
  • November 27, 2020
  • 2
05:16

CancerGRACE

Liquid Biopsy in NSCLC: Does Adding Liquid Biopsy to Tissue Testing Improve Our Ability to Detect Mutations and Administer Targeted Therapy to Patients?

FEATURING Charu Aggarwal
  • 259 views
  • November 27, 2020
  • 1
06:45

GRACE

SCLC Updates: What Are the Leading Immunotherapy Options?

FEATURING Stephen Liu
  • 305 views
  • October 30, 2020
  • 3
05:38

GRACE

Expert Discussion on mNSCLC: What Are the Leading Treatment Options for Patients With Negative Tumor PD-L1?

FEATURING Stephen Liu
  • 329 views
  • October 30, 2020
  • 3
05:45

GRACE

2020 Update on Molecular Abnormalities in NSCLC: How Do MET Exon 14 Skipping Mutations Work? Is Capmatinib Better Performing Than Crizotinib?

FEATURING Joshua Bauml
  • 239 views
  • September 30, 2020
  • 3
05:56

GRACE

The Role of IO for NSCLC Patients With Driver Mutations: What Data Do We Have?

FEATURING Benjamin Levy
  • 184 views
  • September 30, 2020
  • 2
07:43

CancerGRACE

2020 Update on Targeted Therapies in NSCLC PD-L1 Expression: What Are the Leading Options for Patients With Low or Negative PD-L1 Expression and Advanced Non-Squamous NSCLC?

FEATURING Millie Das
  • 105 views
  • September 25, 2020
  • 1
07:55

GRACE

Non-Small Cell Lung Cancer: Is Immunotherapy Safe for Frail Patients With the Advanced Disease? Can TMB Help Tailor Treatment Decisions?

FEATURING Matthew Gubens
  • 50 views
  • June 9, 2020
  • 1
05:13

GRACE

Does Immunotherapy Have Activity in Malignant Pleural Mesothelioma?

FEATURING Millie Das
  • 199 views
  • June 9, 2020
  • 2
06:15

CancerGRACE

Non-Small Cell Lung Cancer: How Does a Positive HER2 Mutation Affect Treatment Decisions?

FEATURING Jack West, Jonathan Riess, Suki Padda
  • 9 views
  • May 28, 2020
06:03

GRACE

ALK+ NSCLC With High PD-L1. What Is the First Line Treatment for Potentially Competing Targets?

FEATURING Jack West, Jonathan Riess, Suki Padda
  • 128 views
  • May 28, 2020
06:00

CancerGRACE

What Is the Importance of MET Amplification Level in EGFR+ NSCLC With MET Amplification? How Should We Tailor Treatment Decisions?

FEATURING Caroline McCoach, Heather Wakelee, Jack West
  • 5 views
  • May 21, 2020
03:45

GRACE

NSCLC EGFR Mutation Treated With Tagrisso: Progression While on Treatment - What Is the Role of Repeating Biopsy?

FEATURING Caroline McCoach, Heather Wakelee, Jack West
  • 4 views
  • May 21, 2020
07:30

CancerGRACE

NSCLC EGFR Mutation and the FLAURA Trial: Is There a Difference in Data Based on Demographics & How Can That Effect Treatment Decisions?

FEATURING Caroline McCoach, Heather Wakelee, Jack West
  • 7 views
  • May 21, 2020
08:20

GRACE

EGFR + NSCLC: Is There a Place for Chemo and the Inclusion of Immunotherapy? Where Does Immunotherapy Fit Into the Mix?

FEATURING Jack West, Heather Wakelee, Caroline McCoach
  • 738 views
  • May 21, 2020
  • 2
04:14

CancerGRACE

EGFR Mutation and High and High PD-L1 in NSCLC: What is the Role of Immunotherapy in Treatment?

FEATURING Caroline McCoach, Heather Wakelee, Jack West
  • 9 views
  • May 21, 2020
05:18

CancerGRACE

Non-Small Cell Lung Cancer: What Are the Recommended Treatments for Common EGFR Mutations?

FEATURING Caroline McCoach, Heather Wakelee, Jack West
  • 116 views
  • May 21, 2020
05:04

CancerGRACE

NSCLC With EGFR Mutation: What Are the Treatment Options with Oligoprogression in Brain vs. Worsening Progression?

FEATURING Caroline McCoach, Heather Wakelee, Jack West
  • 3 views
  • May 21, 2020
07:12

CancerGRACE

NSCLC With EGFR Mutation: Is There a Place for Chemotherapy and an EGFR Inhibitor Concurrently or Sequentially in Treatment Decisions?

FEATURING Caroline McCoach, Heather Wakelee, Jack West
  • 519 views
  • May 21, 2020
  • 4
05:52

CancerGRACE

NSCLC With EGFR Uncommon Exon 20 Mutation: Suggested Treatments, Targeted Therapy, and Clinical Trials

FEATURING Caroline McCoach, Heather Wakelee, Jack West
  • 13 views
  • May 21, 2020
04:20

GRACE

The Challenges of Potential Pneumonitis Following Durvalumab in Stage 3 NSCLC

FEATURING Matthew Gubens, Jack West, Millie Das
  • 10 views
  • March 13, 2020
06:03

CancerGRACE

Would IO Be Beneficial for Stage 3 NSCLC Patient with PDL1-0 After Standard Treatment of Chemo and Radiation?

FEATURING Matthew Gubens, Jack West, Millie Das
  • 128 views
  • March 13, 2020
08:02

CancerGRACE

Best Schedule for Durvalumab for Older Patient in Stage 3 NSCLC After Standard Treatment of Chemo and Radiation

FEATURING Jack West, Matthew Gubens, Millie Das
  • 228 views
  • March 13, 2020
05:12

CancerGRACE

Unresectable NSCLC: What Is TMB and Does it Add Significant Benefit to Guide Treatment Recommendations?

FEATURING Matthew Gubens, Jack West, Millie Das
  • 462 views
  • March 12, 2020
  • 2
08:50

GRACE

Does Checkmate 227's Suggestion of an IO Combination of Ipi + Nivo Offer Another Treatment Option for Advanced NSCLC?

FEATURING Matthew Gubens, Jack West, Millie Das
  • 123 views
  • March 12, 2020
  • 1
10:58

CancerGRACE

Should Molecular Tests Be Considered in Stage 3 NSCLC and Would Outcome Effect Treatment Decisions?

FEATURING Matthew Gubens, Jack West, Millie Das
  • 317 views
  • March 12, 2020
  • 2
09:22

CancerGRACE

Case of 60 y/o Woman with ALK Positive Metastatic NSCLC: Approach to 1st Line Treatment

FEATURING Suki Padda, Jonathan Riess, Jack West
  • 189 views
  • March 13, 2020
06:14

GRACE

Case of ALK Positive Patient with Asymptomatic Brain Metastases: Is the Standard Approach of Focal Radiation Before Beginning ALK Inhibitor Appropriate?

FEATURING Suki Padda, Jonathan Riess, Jack West
  • 9 views
  • March 13, 2020
09:45

GRACE

Treatment for NSCLC Patient Who Developed Resistance to ALK Inhibitors

FEATURING Suki Padda, Jonathan Riess, Jack West
  • 12 views
  • March 13, 2020
11:11

GRACE

Is the Standard Treatment the Best Approach for Stage 3 Frail Patient with Unresectable NSCLC?

FEATURING Matthew Gubens, Jack West, Millie Das
  • 389 views
  • March 13, 2020
  • 1
06:43

CancerGRACE

Should We Continue the ALK Inhibitor in NSCLC Patient with Brain Mets and Progression in Body when Transitioning to a Chemo Based Approach?

FEATURING Suki Padda, Jonathan Riess, Jack West
  • 117 views
  • March 13, 2020
10:53

CancerGRACE

Is There a Role for Combination Therapies Like Chemo/Radio and IO for NSCLC Patient Progressed After Success on ALK Inhibitors?

FEATURING Suki Padda, Jonathan Riess, Jack West
  • 329 views
  • March 13, 2020
09:53

GRACE

Stage 3 NSCLC - Standard Concurrent Chemo + Radiation, Followed by IO, as Suggest in Pacific Trial: Does the Timing of Treatment Make a Difference in Response?

FEATURING Matthew Gubens, Jack West, Millie Das
  • 168 views
  • March 2, 2020
11:27

CancerGRACE

Stage 3 NSCLC: Is the Standard Treatment of Chemo and Radiation Followed by IO the Best Treatment Approach for a Frail Patient With Potential Competing Risks?

FEATURING Matthew Gubens, Jack West, Millie Das
  • 274 views
  • March 2, 2020
11:26

CancerGRACE

Case Based Discussion on Stage 3 NSCLC: Should We Do Molecular Tests and Would That Effect the Treatment Decision?

FEATURING Matthew Gubens, Jack West, Millie Das
  • 338 views
  • January 29, 2020
  • 2
05:24

GRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: How Promising is Lurbinectedin for Relapsed SCLC?

FEATURING Jack West, Benjamin Levy, Charu Aggarwal
  • 870 views
  • September 24, 2019
  • 3
05:32

CancerGRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: Short Discussion on KRAS G12C as a Target

FEATURING Jack West, Benjamin Levy, Charu Aggarwal
  • 171 views
  • September 24, 2019
06:02

CancerGRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: Circulating Tumor DNA for Monitoring Disease Status

FEATURING Jack West, Benjamin Levy, Charu Aggarwal
  • 89 views
  • September 24, 2019
05:53

CancerGRACE

CancerGRACE's ASCO 2019 Update on Lung Cancer: Retrospective Analysis of STK11 and KEAP Targets

FEATURING Jack West, Benjamin Levy, Charu Aggarwal
  • 90 views
  • September 24, 2019
03:55

CancerGRACE

CancerGRACE's ASCO 2019 Update on Stage IV NSCLC: New Targets - RET

FEATURING Jack West, Benjamin Levy, Charu Aggarwal
  • 140 views
  • September 24, 2019
  • 1
06:33

CancerGRACE

CancerGRACE's ASCO 2019 Highlights and New Approaches in Stage IV NSCLC: Long Term Outcomes with Pembrolizumab

FEATURING Jack West, Benjamin Levy, Charu Aggarwal
  • 274 views
  • September 24, 2019
  • 2
07:14

CancerGRACE

CancerGRACE's ASCO 2019 Highlights and New Approaches in Stage IV NSCLC: New Targets - MET

FEATURING Jack West, Benjamin Levy, Charu Aggarwal
  • 63 views
  • September 24, 2019
06:33

CancerGRACE

CancerGRACE's 2019 ASCO Highlights in Advanced NSCLC: What is the Long-Term Survival Benefit With Pembrolizumab?

FEATURING Jack West, Benjamin Levy, Charu Aggarwal
  • 217 views
  • September 6, 2019
  • 1
06:38

CancerGRACE

CancerGRACE's 2019 ASCO Highlights on Adjuvant Afatinib in Stage II and III EGFR+ NSCLC - What Have We Learned?

FEATURING Jack West, Benjamin Levy, Charu Aggarwal
  • 462 views
  • September 6, 2019
  • 3
07:26

CancerGRACE

CancerGRACE's 2019 ASCO Highlights on Stage I NSCLC Adjuvant Chemotherapy - Retrospective Japanese Data

FEATURING Jack West, Benjamin Levy, Charu Aggarwal
  • 18 views
  • September 6, 2019
21:24

GRACE

Is There a Role for IO in EGFR+ Metastatic Lung Cancer?

FEATURING Helena Yu
  • 4,767 views
  • August 2, 2019
  • 28
47:56

CancerGRACE

Initial Treatment and Acquired Resistance in Advanced Lung Cancer & Targeting BRAF, RET, and BRAF

FEATURING Joshua Bauml, Joshua K. Sabari
  • 199 views
  • August 2, 2019
  • 1
21:58

CancerGRACE

Q&A on Targeted Therapies in Advanced Lung Cancer

FEATURING Joshua Bauml
  • 8 views
  • August 2, 2019
19:19

GRACE

Introduction to Next Generation Sequencing in Metastatic Lung Cancer: Current Status, Barriers and Emerging Targets

FEATURING Joshua Bauml
  • 618 views
  • August 2, 2019
  • 2
23:26

CancerGRACE

EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC

FEATURING Helena Yu
  • 170 views
  • July 22, 2019
  • 1
09:30

GRACE

Q&A on EGFR Initial Treatment and Acquired Resistance in Advanced NSCLC

FEATURING Helena Yu
  • 25 views
  • July 22, 2019
  • 1
07:53

CancerGRACE

Optimal First Line Treatment of EGFR+ Advanced NSCLC: First and Second Generation EGFR TKIs

FEATURING Jack West
  • 106 views
  • July 22, 2019
18:32

CancerGRACE

Optimal First Line Treatment of EGFR+ Advanced NSCLC: Osimertinib vs. Standard of Care EGFR TKIs and Chemo

FEATURING Jack West
  • 550 views
  • July 22, 2019
  • 2
17:04

CancerGRACE

Optimal First Line Treatment of EGFR+ Advanced NSCLC: Dacomitinib, Erlotinib vs Bevacizumab, Gefitinib+Chemo

FEATURING Jack West
  • 668 views
  • July 22, 2019
  • 2
17:10

CancerGRACE

Targeted Therapies in Advanced Lung Cancer: What is the Role of Rebiopsy?

FEATURING Hossein Borghaei
  • 453 views
  • July 22, 2019
  • 3
26:54

CancerGRACE

Discussion/Q&A on Targeted Therapies in Advanced Lung Cancer

FEATURING Hossein Borghaei
  • 16 views
  • July 22, 2019
15:23

GRACE

Targeted Therapies in Metastatic NSCLC: Liquid Biopsies as a New Option in Patient Care and Day-to-Day Management

FEATURING Charu Aggarwal
  • 616 views
  • July 22, 2019
  • 3
02:13

CancerGRACE

Immunotherapy in Stage lll NSCLC - The Pacific Trial and Imfinzi

FEATURING Karen Kelly
  • 158 views
  • January 17, 2019
01:54

CancerGRACE

Tumor Mutation Burden in Patients with Non-Squamous NSCLC: Current Status

FEATURING Sandip Patel
  • 12 views
  • January 17, 2019
02:41

CancerGRACE

Evolving Standards for Molecular Testing in Advanced NSCLC

FEATURING Sandip Patel
  • 14 views
  • January 17, 2019
02:05

CancerGRACE

Combinations of Immunotherapy Agents in Advanced NSCLC: Current Status

FEATURING Sandip Patel
  • 9 views
  • January 17, 2019
02:17

GRACE

The Basics of Managing Immune-Mediated Side Effects in NSCLC

FEATURING Sandip Patel
  • 16 views
  • January 17, 2019
03:50

CancerGRACE

What Should Patients With Rapid Progression in Advanced NSCLC Through 1st Line Treatment Receive Next?

FEATURING Jack West
  • 180 views
  • January 17, 2019
04:46

GRACE

"Consolidation" Radiation After a Good Response to First Line Therapy in Advanced and Metastatic NSCLC - Who and Why?

FEATURING Jack West
  • 7 views
  • January 17, 2019
06:57

CancerGRACE

Chemotherapy and Immunotherapy Combinations in Advanced Non-Squamous NSCLC

FEATURING Jack West
  • 156 views
  • January 17, 2019
05:39

CancerGRACE

Chemo Immuno Therapy Combinations in Advanced Squamous NSCLC

FEATURING Jack West
  • 175 views
  • January 17, 2019
  • 1
07:13

CancerGRACE

Does Immunotherapy Work in Patients with Driver Mutations Like EGFR and ALK in Advanced NSCLC?

FEATURING Jack West
  • 231 views
  • January 17, 2019
04:09

CancerGRACE

EGFR TKI Gilotrif(Afatinib) in Metastatic Squamous NSCLC

FEATURING Vamsidhar Velcheti
  • 192 views
  • January 17, 2019
  • 1
04:24

CancerGRACE

Lung Cancer Immunotherapy- Is There Anything Better than PDL1

FEATURING Vamsidhar Velcheti
  • 105 views
  • January 17, 2019
03:20

GRACE

MET as a Target in Advanced NSCLC

FEATURING Vamsidhar Velcheti
  • 15 views
  • January 17, 2019
04:33

CancerGRACE

The Changing Landscape of 1L Treatment of ALK-Positive Advanced NSCLC: What Does the ALEX Data Show?

FEATURING Alice Shaw
  • 37 views
  • January 17, 2019
06:02

GRACE

Patterns of Resistance in ALK Positive NSCLC

FEATURING Alice Shaw
  • 220 views
  • January 17, 2019
  • 1
05:04

GRACE

Controlling Brain Metastases in Patients with Molecular Driven Advanced NSCLC

FEATURING Alice Shaw
  • 24 views
  • January 17, 2019
02:14

CancerGRACE

Immunotherapy for Previously Treated Patients with NSCLC

FEATURING Karen Reckamp
  • 8 views
  • January 17, 2019
04:50

CancerGRACE

New Options in Acquired Resistance for ALK+ Metastatic Non-small Cell Lung Cancer (NSCLC)

FEATURING Nathan Pennell
  • 229 views
  • January 17, 2019
03:45

CancerGRACE

The Role for Immunotherapy in Patients with a Driver Mutation Lung Cancer

FEATURING Nathan Pennell
  • 12 views
  • January 17, 2019
03:35

CancerGRACE

Liquid Biopsies for Broad Genomic Testing in Lung Cancer

FEATURING Nathan Pennell
  • 24 views
  • January 17, 2019
03:53

CancerGRACE

Liquid Biopsies for EGFR T790M Advanced NSCLC

FEATURING Nathan Pennell
  • 11 views
  • January 17, 2019
02:45

CancerGRACE

The Role of Angiogenesis in Previously Treated NSCLC

FEATURING Karen Reckamp
  • 10 views
  • January 29, 2019
09:07

CancerGRACE

Advanced Non Squamous NSCLC, High PD-L1, No Mutation - Optimal 1st Line? - Case Based Panel Discussion

FEATURING Jack West, Zofia Piotrowska, Taofeek Owonikoko
  • 211 views
  • January 29, 2019
12:59

CancerGRACE

Advanced Non Squamous NSCLC, Low PD-L1, No Mutation - Best Systemic Therapy? - Case Based Panel Discussion

FEATURING Jack West, Zofia Piotrowska, Taofeek Owonikoko
  • 230 views
  • January 29, 2019
11:09

CancerGRACE

Case Based Panel Discussion - Fit Patient Adv Squamous NSCLC Low Tumor PD-L1

FEATURING Jack West, Zofia Piotrowska, Taofeek Owonikoko
  • 7 views
  • January 29, 2019
08:18

GRACE

Lung Cancer Case Based Panel Discussion - EGFR and High PDL-1, Choosing Targeted Therapy or Immunotherapy

FEATURING Jack West, Zofia Piotrowska, Taofeek Owonikoko
  • 144 views
  • January 29, 2019
  • 1
09:21

CancerGRACE

Case Based Panel Discussions - Metastatic Squamous NSCLC Low Tumor PD-L1 Frail Patient - Treatment?

FEATURING Jack West, Zofia Piotrowska, Taofeek Owonikoko
  • 7 views
  • January 29, 2019
08:17

CancerGRACE

Rapid Progression Lung Adenocarcinoma High PD-L1 - How Do You Treat? Case Based Panel Discussion

FEATURING Jack West, Zofia Piotrowska, Taofeek Owonikoko
  • 57 views
  • January 29, 2019
11:15

GRACE

ASCO 2018 - Keynote 042 - Keytruda as a Single Agent Compared to Doublet Chemotherapy for NSCLC

FEATURING Karen Kelly, Jack West, Sandip Patel
  • 346 views
  • January 29, 2019
12:26

CancerGRACE

ASCO 2018 - Potential Showdown of Two Positive Trials? Keynote 407 and IMPower 131

FEATURING Karen Kelly, Jack West, Sandip Patel
  • 12 views
  • January 29, 2019
11:29

CancerGRACE

ASCO 2018 Keynote189 - Cisplatin or Carboplatin with Alimta & Keytruda - Practice Changing Approach?

FEATURING Karen Kelly, Jack West, Sandip Patel
  • 12 views
  • January 29, 2019
09:40

CancerGRACE

ASCO 2018 - Checkmate 227 - Combinations of Nivolumab and Ipilimumab, or Nivolumab and Chemo

FEATURING Karen Kelly, Jack West, Sandip Patel
  • 12 views
  • January 29, 2019
07:35

CancerGRACE

ASCO 2018 - Will Taking Mod to High Dose Steroids Affect Lung Cancer Pts on Immunotherapy?

FEATURING Karen Kelly, Jack West, Sandip Patel
  • 7 views
  • January 29, 2019
09:11

CancerGRACE

ASCO 2018 - Tarceva or Tarceva with Avastin as 1st Line for EGFR Pos. NSCLC vs. Tagrisso or Vizimpro

FEATURING Karen Kelly, Jack West, Sandip Patel
  • 7 views
  • January 29, 2019
06:27

CancerGRACE

ASCO 2018 - Tarceva Combined with Carboplatin & Alimta - Given Upfront - Affect Pace of Disease?

FEATURING Karen Kelly, Jack West, Sandip Patel
  • 18 views
  • January 29, 2019
02:52

CancerGRACE

ASCO 2018 - Combining Metformin with Standard EGFR Therapy - Is the Jury Still Out

FEATURING Karen Kelly, Jack West, Sandip Patel
  • 8 views
  • January 29, 2019
03:34

GRACE

ASCO 2018 - Keynote 158 - Keytruda in Previously Treated, Now Relapsing Patients with SCLC

FEATURING Karen Kelly, Jack West, Sandip Patel
  • 9 views
  • January 29, 2019
04:26

GRACE

ASCO 2018 - Dream Study - Chemo with Imfinzi (durvalumab) for Mesothelioma

FEATURING Karen Kelly, Jack West, Sandip Patel
  • 21 views
  • January 29, 2019
25:01

CancerGRACE

OncTalk 2018 - Newer Technologies in Radiation - Local Therapies for Metastatic Lung Cancer

FEATURING Vivek Mehta
  • 8 views
  • January 30, 2019
21:07

CancerGRACE

OncTalk 2018 - Novel Indications for Local Therapy in Adv NSCLC - Local Therapies for Metastatic LC

FEATURING Puneeth Iyengar
  • 8 views
  • January 30, 2019
19:01

GRACE

NSCLC - Local Therapies for Metastatic LC

FEATURING Eric Vallieres
  • 191 views
  • January 30, 2019
27:13

CancerGRACE

OncTalk 2018 - Systemic Therapies for Advanced NSCLC - Local Therapies for Metastatic LC

FEATURING Jack West
  • 10 views
  • January 30, 2019
45:31

CancerGRACE

OncTalk 2018 - Panel Discussion and Q&A - Local Therapies for Metastatic LC

FEATURING Eric Vallieres, Jack West, Vivek Mehta, Puneeth Iyengar
  • 9 views
  • January 30, 2019